Table 5. Treatment-related adverse events.
| Adverse event | Any grade | Grades 3–4 | |||||
|---|---|---|---|---|---|---|---|
| HAIC (n=37) | SYS (n=74) | P value | HAIC (n=37) | SYS (n=74) | P value | ||
| Rash | 5 (13.5%) | 25 (33.8%) | 0.08 | 0 | 0 | – | |
| Fever | 11 (29.7%) | 23 (31.1%) | 0.88 | 0 | 0 | – | |
| Abdominal pain | 9 (24.3%) | 10 (13.5%) | 0.15 | 1 (2.7%) | 3 (4.1%) | >0.99 | |
| Vomiting | 7 (18.9%) | 29 (39.2%) | 0.03 | 0 | 11 (14.8%) | 0.04 | |
| Fatigue | 4 (10.8%) | 31 (41.9%) | <0.01 | 0 | 0 | – | |
| Leukopenia | 3 (8.1%) | 10 (13.5%) | 0.31 | 0 | 7 (9.5%) | 0.12 | |
| Anemia | 7 (18.9%) | 36 (48.6%) | <0.01 | 0 | 9 (12.2%) | 0.07 | |
| Thrombocytopenia | 4 (10.8%) | 21 (28.4%) | 0.01 | 0 | 2 (2.7%) | 0.48 | |
| Elevated ALT | 9 (24.3%) | 33 (44.6%) | 0.04 | 1 (2.7%) | 3 (4.1%) | >0.99 | |
| Elevated AST | 13 (35.1%) | 28 (37.8%) | 0.78 | 1 (2.7%) | 4 (5.4%) | 0.60 | |
| Hyperbilirubinemia | 7 (18.9%) | 12 (16.2%) | 0.72 | 2 (5.4%) | 3 (4.1%) | >0.99 | |
| Hypoalbuminemia | 5 (13.5%) | 16 (21.6%) | 0.30 | 1 (2.7%) | 0 | 0.48 | |
| Elevated creatinine | 2 (5.4%) | 9 (12.2%) | 0.39 | 0 | 0 | – | |
| Sensory neuropathy | 4 (10.8%) | 18 (24.3%) | 0.18 | 0 | 0 | – | |
ALT, alanine transaminase; AST, aspartate transaminase; HAIC, hepatic arterial infusion chemotherapy; SYS, systemic chemotherapy.